This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 29/1/140    most recent ATVBAHA.108.171223v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Millar, J. S. Articles by Rader, D. J. Search for Related Content PubMed PubMed Citation Articles by Millar, J. S. Articles by Rader, D. J.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29:140.)
© 2009 American Heart Association, Inc.

Clinical and Population Studies

Potent and Selective PPAR- Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome

John S. Millar; Danielle Duffy; Ramprasad Gadi; LeAnne T. Bloedon; Richard L. Dunbar; Megan L. Wolfe; Rajesh Movva; Ashish Shah; Ilia V. Fuki; Mary McCoy; Cynthia J. Harris; Ming-Dauh Wang; Daniel C. Howey; Daniel J. Rader

From the Departments of Pharmacology (J.S.M.) and Medicine (D.D., R.G., L.T.B., R.L.D., M.L.W., A.S., I.V.F., M.M., D.J.R.), Institute for Translational Research and Therapeutics, University of Pennsylvania, Philadelphia; Pennsylvania Hospital (R.M.), Philadelphia; and Eli Lilly and Company (C.J.H., M.-D.W., D.C.H.), Indianapolis, Ind.

Correspondence to John S. Millar, PhD, University of Pennsylvania, 652 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104. E-mail jsmillar{at}mail.med.upenn.edu

Objective— The study of PPAR- activation on apoA-I production in humans has been limited to fibrates, relatively weak PPAR- agonists that may have other molecular effects. We sought to determine the effect of a potent and highly specific PPAR- agonist, LY518674, on apoA-I, apoA-II, and apoB-100 kinetics in humans with metabolic syndrome and low levels of HDL cholesterol (C).

Methods and Results— Subjects were randomized to receive LY518674 (100 µg) once daily (n=13) or placebo (n=15) for 8 weeks. Subjects underwent a kinetic study using a deuterated leucine tracer to measure apolipoprotein production and fractional catabolic rates (FCR) at baseline and after treatment. LY518674 significantly reduced VLDL-C (–38%, P=0.002) and triglyceride (–23%, P=0.002) levels whereas LDL-C and HDL-C levels were unchanged. LY518674 significantly reduced VLDL apoB-100 (–12%, P=0.01) levels, attributable to an increased VLDL apoB-100 FCR with no change in VLDL apoB-100 production. IDL and LDL apoB-100 kinetics were unchanged. LY518674 significantly increased the apoA-I production rate by 31% (P<0.0001), but this was accompanied by a 33% increase in the apoA-I FCR (P=0.002), resulting in no change in plasma apoA-I. There was a 71% increase in the apoA-II production rate (P<0.0001) accompanied by a 25% increase in the FCR (P<0.0001), resulting in a significant increase in plasma apoA-II.

Conclusions— Activation of PPAR- with LY518674 (100 µg) in subjects with metabolic syndrome and low HDL-C increased the VLDL apoB-100 FCR consistent with enhanced lipolysis of plasma triglyceride. Significant increases in the apoA-I and apoA-II production rates were accompanied by increased FCRs resulting in no change in HDL-C levels. These data indicate a major effect of LY518674 on the production and clearance of apoA-I and HDL despite no change in the plasma concentration. The effect of these changes on reverse cholesterol transport remains to be determined.

We studied apoA-I and apoA-II metabolism after treatment with a potent and specific PPAR- agonist, LY518674, or placebo for 8 weeks. LY518674 increased apoA-I and apoA-II production and fractional catabolic rates leaving HDL-C levels unchanged. LY518674 significantly increases apoA-I production and clearance despite no change in HDL.

Key Words: apolipoproteins • cardiovascular disease prevention • hyperlipoproteinemia • lipoproteins